Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report

23Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Myasthenia gravis (MG) is an autoimmune disease, with immune reactivity against the post-synaptic endplate of the neuromuscular junction. Apart from symptomatic treatment with choline esterase blockers, many patients also require immunomodulatory treatment. Despite existing treatment options, some patients are treatment refractory. We describe a patient with severe MG refractory to corticosteroids, four oral immunosuppressants, cyclophosphamide, rituximab and bortezomib who was treated with autologous haematopoietic stem cell transplantation. Two years after this, the patient has significantly improved in objective tests and in quality of life and leads an active life. Diplopia is her only remaining symptom and she is completely free of medication for MG. We believe that autologous haematopoietic stem cell transplantation can be an effective therapeutic option for carefully selected cases of severe, treatment refractory MG.

Cite

CITATION STYLE

APA

Håkansson, I., Sandstedt, A., Lundin, F., Askmark, H., Pirskanen, R., Carlson, K., … Hägglund, H. (2017). Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report. Neuromuscular Disorders, 27(1), 90–93. https://doi.org/10.1016/j.nmd.2016.09.020

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free